Singapore, April 24 -- Cognitive impairment associated with cancer, also known as "chemobrain", has gained recognition as a complication of the disease and its treatment, as it can negatively affect the daily lives of cancer patients and survivors.

Given the extent of impact from chemobrain on patients, it will be useful if patients who are at higher risk of developing such symptoms could be pre-emptively identified with the use of a standardised, quantitative biomarker.

With this in mind, a team led by Associate Professor Alexandre Chan from NUS Pharmacy started to investigate levels of biomarkers in relation to chemobrain, to better understand its cause.

The team recently characterised plasma levels of the biomarker dehydroepiandrost...